Retreatment after loss to follow-up reduces mortality in patients with multidrug/rifampicin-resistant tuberculosis

Author:

Choi Hongjo,Mok Jeongha,Ae Kang YoungORCID,Jeong DawoonORCID,Kang Hee-YeonORCID,Kim Hee JinORCID,Kim Hee-SunORCID,Jeon Doosoo

Abstract

BackgroundThis study evaluated the risk factors of long-term mortality in patients with multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB) in South Korea who were lost to follow-up (LTFU).MethodsThis was a retrospective longitudinal follow-up study using an integrated database constructed by data linkage of the three national databases, which included 7226 cases of MDR/RR-TB notified between 2011 and 2017 in South Korea. Post-treatment outcomes of patients who were LTFU were compared with those of patients who achieved treatment success.ResultsOf the 7226 MDR/RR-TB cases, 730 (10.1%) were LTFU. During a median follow-up period of 4.2 years, 101 (13.8%) of the LTFU patients died: 25 deaths (3.4%) were TB related and 76 (10.4%) were non-TB related. In the LTFU group, the adjusted hazard ratio (aHR) of all-cause mortality (aHR 2.50, 95% CI 1.99–3.15, p<0.001), TB-related mortality (aHR 5.38, 95% CI 3.19–9.09, p<0.001) and non-TB-related mortality (HR 2.21, 95% CI 1.70–2.87, p<0.001) was significantly higher than that in the treatment success group. Independent risk factors for all-cause mortality in the LTFU group were age >55 years, fluoroquinolone resistance, cancer and no retreatment. In the LTFU patients who did not receive retreatment, the risk of non-TB-related mortality (aHR 5.00, 95% CI 1.53–16.37, p=0.008) and consequent all-cause mortality (aHR 2.18, 95% CI 1.08–4.40, p=0.030) was significantly higher than that of patients who received retreatment.ConclusionNon-TB-related mortality was the main cause of death and might be reduced by retreatment in LTFU patients with MDR/RR-TB.

Funder

National Evidence-based Healthcare Collaborating Agency

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference31 articles.

1. Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients

2. Lost to follow-up and associated factors among patients with drug resistant tuberculosis in Ethiopia: a systematic review and meta-analysis;Andargie;PLoS One,2021

3. Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review

4. World Health Organization . Global Tuberculosis Report 2021. 2021. www.who.int/publications/i/item/9789240037021. Date last accessed: 25 February 2023.

5. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic;Kim;Int J Tuberc Lung Dis,2001

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3